Nutraceutix has received been granted a patent by the United States Patent Office for its dual polymer Controlled Delivery Technology (CDT) platform.
In collaboration with Dr. Reza Fassihi of Temple University School of Pharmacy in Philadelphia, Nutraceutix has been developing dietary supplements, OTC products and prescription drugs which employ the novel delivery system for oral dosage.
The CDT technology has also been successfully deployed in prototype formulations of established pharmaceuticals such as nifedipine, theophylline, propanolol, diltiazem, and verapamil, the company said.
In addition, the technology has allowed Nutraceutix to develop formulations for the OTC and nutritional industries, such as glucosamine, glucosamine/chondroitin, niacin, pseudoephedrine, caffeine, vitamin C, Novasoy, and other difficult compounds and branded ingredients.
David T. Howard, president and CEO of Nutraceutix, said: "The new CDT dual polymer patent in conjunction with the previously issued CDT salt patent and our recently filed third CDT patent application provides Nutraceutix with three novel drug delivery platforms.
"Nutraceutix is currently addressing some of the most challenging hurdles of oral drug delivery such as difficult to tablet ingredients, or poorly soluble active ingredients. These three CDT platforms constitute a compelling reason for OTC, nutraceutical and pharmaceutical companies to partner with Nutraceutix for their controlled delivery systems."